HSP90AA1 and COVID-19: Actually, transcriptomic profiling of SARS-CoV-2 infected human cell lines identified HSP90 as target for COVID-19 therapy [134], and for example geldanamycin, the most studied and prominent HSP90 inhibitor, was proposed to treat COVID-19 (Figure 7) [134,135].